Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | SMARCB1 negative |
Therapy | Alvocidib |
Indication/Tumor Type | rhabdoid cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCB1 negative | rhabdoid cancer | sensitive | Alvocidib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228). | 18223228 |
PubMed Id | Reference Title | Details |
---|---|---|
(18223228) | Rhabdoid tumor growth is inhibited by flavopiridol. | Full reference... |